PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 202 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Colposcopia: Cómo prepararse y qué saber August 6, 2020 ESMO Award for Immuno-Oncology 2025 Recipient Announced November 4, 2025 Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For... April 7, 2021 EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical... October 3, 2025 Load more HOT NEWS When Breast Cancer Patient Comes Into His Shop, Barber Shaves His... New on NCI Websites for October 2018 Professor Ian Tomlinson: “Philanthropy is priceless to science” Smoking addiction killed my grandfather – now it’s up to the...
